Promacta is a brand name of eltrombopag, approved by the FDA in the following formulation(s):
PROMACTA (eltrombopag olamine - tablet; oral)
Manufacturer: GLAXOSMITHKLINE
Approval date: November 20, 2008
Strength(s): EQ 25MG ACID, EQ 50MG ACID [RLD]
Manufacturer: GLAXOSMITHKLINE
Approval date: September 8, 2009
Strength(s): EQ 75MG ACID
Manufacturer: GLAXOSMITHKLINE
Approval date: October 20, 2011
Strength(s): EQ 12.5MG ACID
Has a generic version of Promacta been approved?
No. There is currently no therapeutically equivalent version of Promacta available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Promacta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Metal complexes
Patent 6,280,959
Issued: August 28, 2001
Inventor(s): Gleason; John G. & Luengo; Juan I.
Assignee(s): SmithKline Beecham Corporation
The invention describes zinc chelated dimeric cell-surface receptor ligands, pharmaceutical compositions containing these compounds, methods of using these compounds as agonist of dimeric cell-surface receptors. Novel processes used in preparing the compounds are also described. Further, the invention describes novel receptor binding moieties of the zinc chelated cell-surface receptor ligands.Patent expiration dates:
- October 30, 2018✓✓✓
- October 30, 2018
Thrombopoietin mimetics
Patent 7,160,870
Issued: January 9, 2007
Inventor(s): Duffy; Kevin J. & Erickson-Miller; Connie & Jenkins; Julian & Luengo; Juan I. & Visonneau; Sophie
Assignee(s): SmithKline Beecham Corporation
Glaxo Group Limited
Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.Patent expiration dates:
- December 8, 2021✓✓✓
- December 8, 2021
Thrombopoietin mimetics
Patent 7,332,481
Issued: February 19, 2008
Inventor(s): Duffy; Kevin J. & Erickson-Miller; Connie & Jenkins; Julian & Luengo; Juan & Price; Alan T. & Shaw; Antony N. & Visonneau; Sophie & Wiggall; Kenneth
Assignee(s): SmithKline Beecham Corporation
Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.Patent expiration dates:
- May 24, 2021✓
- May 24, 2021
Thrombopoietin mimetics
Patent 7,452,874
Issued: November 18, 2008
Inventor(s): Duffy; Kevin J. & Luengo; Juan I. & Shaw; Antony N. & Wiggall; Kenneth
Assignee(s): SmithKline Beecham Corp.
Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.Patent expiration dates:
- May 24, 2021✓✓
- May 24, 2021
Thrombopoietin mimetics
Patent 7,473,686
Issued: January 6, 2009
Inventor(s): Duffy; Kevin J. & Erickson-Miller; Connie & Jenkins; Julian & Luengo; Juan I. & Visonneau; Sophie
Assignee(s): SmithKline Beecham Corp.
Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.Patent expiration dates:
- May 24, 2021✓✓✓
- May 24, 2021
3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine)
Patent 7,547,719
Issued: June 16, 2009
Inventor(s): Moore; Stephen
Assignee(s): SmithKline Beecham Corp.
An improved thrombopoietin mimetic, the bis-(monoethanolamine) salt of 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid.Patent expiration dates:
- July 13, 2025✓✓✓
- July 13, 2025
Thrombopoietin mimetics
Patent 7,790,704
Issued: September 7, 2010
Inventor(s): Duffy; Kevin J. & Erickson-Miller; Connie & Jenkins; Julian & Luengo; Juan I.
Assignee(s): GlaxoSmithKline, LLC
Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.Patent expiration dates:
- May 24, 2021✓
- May 24, 2021
3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Patent 7,795,293
Issued: September 14, 2010
Inventor(s): Moore; Stephen
Assignee(s): GlaxoSmithKline LLC
An improved thrombopoietin mimetic, the bis-(monoethanolamine) salt of 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid.Patent expiration dates:
- May 21, 2023✓
- May 21, 2023
3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Patent 8,052,993
Issued: November 8, 2011
Inventor(s): Muller; Francis X & Kapsi; Shivakumar G
Assignee(s): GlaxoSmithKline LLC
Disclosed are novel pharmaceutical compositions containing 3′-[(2Z)-[1-(3,4-dimethylphenyl) -1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.Patent expiration dates:
- August 1, 2027✓✓
- August 1, 2027
3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Patent 8,052,994
Issued: November 8, 2011
Inventor(s): Muller; Francis X. & Kapsi; Shivakumar G.
Assignee(s): GlaxoSmithKline LLC
Disclosed are novel pharmaceutical compositions containing 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.Patent expiration dates:
- August 1, 2027✓✓
- August 1, 2027
3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Patent 8,062,665
Issued: November 22, 2011
Inventor(s): Muller; Francis X & Kapsi; Shivakumar G
Assignee(s): GlaxoSmithKline LLC
Disclosed are novel pharmaceutical compositions containing 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.Patent expiration dates:
- August 1, 2027✓✓
- August 1, 2027
3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Patent 8,071,129
Issued: December 6, 2011
Inventor(s): Muller; Francis X & Kapsi; Shivakumar G
Assignee(s): GlaxoSmithKline LLC
Disclosed are novel pharmaceutical compositions containing 3′-[(2Z)-[1-(3,4-dimethylphenyl) -1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.Patent expiration dates:
- August 1, 2027✓✓
- August 1, 2027
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- November 20, 2013 - NEW CHEMICAL ENTITY
- November 20, 2015 - ORPHAN DRUG EXCLUSIVITY
See also...
- Promacta Consumer Information (Drugs.com)
- Promacta Consumer Information (Wolters Kluwer)
- Promacta Consumer Information (Cerner Multum)
- Promacta Advanced Consumer Information (Micromedex)
- Promacta AHFS DI Monographs (ASHP)
- Eltrombopag Consumer Information (Wolters Kluwer)
- Eltrombopag Consumer Information (Cerner Multum)
- Eltrombopag Advanced Consumer Information (Micromedex)
- Eltrombopag AHFS DI Monographs (ASHP)
No comments:
Post a Comment